NautaDutilh assists Dezima Pharma, a Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia, and its shareholders, as lead counsel, in the acquisition by Amgen.
Dezima's lead molecule is TA-8995, an oral, once-daily cholesteryl ester transfer protein (CETP) inhibitor. In a Phase 2b clinical trial for dyslipidemia, TA-8995 reduced low-density lipoprotein cholesterol (LDL-C) by 45 to 48 percent compared to baseline. LDL-C reduction was consistent when TA-8995 was administered as monotherapy or in combination with statins. The cash purchase price amounts to US$300 million in cash at closing and up to US$1.25 billion in additional payments if certain development and sales milestones are achieved.
For more information, please be referred to Amgen's press release.
The NautaDutilh team was led by partners Christiaan de Brauw and Ruud Smits and senior associates Rebecca Pinto and Rianna Dekkers. The remainder of the team consisted of Nico Blom, Wijnand Bossenbroek, Herman Speyart, Lonneke van Moorselaar, Frederike Manzoni, Bart van Kempen, Janneke Speetjens, Julian Blüm, Jeroen Boelens, Florine Kuipéri, Vincent Dogan.